| 000 | 02615 a2200649 4500 | ||
|---|---|---|---|
| 005 | 20250515030448.0 | ||
| 264 | 0 | _c20071109 | |
| 008 | 200711s 0 0 eng d | ||
| 022 | _a1078-0432 | ||
| 024 | 7 |
_a10.1158/1078-0432.CCR-06-0361 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aInamoto, Teruo | |
| 245 | 0 | 0 |
_aAnti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. _h[electronic resource] |
| 260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cJun 2006 |
||
| 300 |
_a3470-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _ximmunology |
| 650 | 0 | 4 | _aAntigen-Antibody Reactions |
| 650 | 0 | 4 | _aBinding Sites |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 |
_aCell Cycle _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aCyclin-Dependent Kinase 2 _xmetabolism |
| 650 | 0 | 4 |
_aCyclin-Dependent Kinase Inhibitor p27 _xbiosynthesis |
| 650 | 0 | 4 |
_aDipeptidyl Peptidase 4 _xbiosynthesis |
| 650 | 0 | 4 | _aDipeptidyl-Peptidase IV Inhibitors |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 |
_aExtracellular Matrix _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aG1 Phase _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aRetinoblastoma Protein _xmetabolism |
| 650 | 0 | 4 |
_aS Phase _xdrug effects |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 650 | 0 | 4 | _aTransplantation, Heterologous |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aYamochi, Tadanori | |
| 700 | 1 | _aOhnuma, Kei | |
| 700 | 1 | _aIwata, Satoshi | |
| 700 | 1 | _aKina, Shinichiro | |
| 700 | 1 | _aInamoto, Sakiko | |
| 700 | 1 | _aTachibana, Masaaki | |
| 700 | 1 | _aKatsuoka, Yoji | |
| 700 | 1 | _aDang, Nam H | |
| 700 | 1 | _aMorimoto, Chikao | |
| 773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 12 _gno. 11 Pt 1 _gp. 3470-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1078-0432.CCR-06-0361 _zAvailable from publisher's website |
| 999 |
_c16337454 _d16337454 |
||